Skip to main content
Journal cover image

Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial.

Publication ,  Journal Article
McClernon, FJ; Hiott, FB; Westman, EC; Rose, JE; Levin, ED
Published in: Psychopharmacology (Berl)
November 2006

RATIONALE: Despite established links between nicotine dependence and depression, little research has examined the effects of nicotine on depression symptoms. OBJECTIVE: This study evaluated the acute and chronic effects of transdermal nicotine in nonsmokers with baseline depression symptoms during a 4-week, double-blind, placebo-controlled trial. METHODS: Nonsmokers with scores >or=10 on the Center for Epidemiological Studies Depression scale (CES-D) were recruited from the community. Mood and cognitive performance were measured at baseline (day 0) and at 1, 8, 21, and 28 days. Participants were randomly assigned to wear a placebo or nicotine patch for 4 weeks (3.5 mg/day during weeks 1 and 4; 7 mg/day during weeks 2 and 3). The final sample consisted of 11 nonsmokers with a mean baseline CES-D score of 27.36 (SD=10.53). RESULTS: Salivary nicotine levels indicated the majority of participants were compliant with treatment. Acute nicotine did not alter mood. After adjusting for baseline values, chronic nicotine resulted in a significant decline in CES-D scores at day 8 (3.5 mg/day), but returned to placebo levels by the last visit. This return to baseline levels was coincident with a decrease in nicotine administration from 7 to 3.5 mg/day. A similar trend for improved response inhibition as measured by the Conners Continuous Performance Task was also observed. Reported side effects were infrequent and minimal. CONCLUSION: These findings suggest a role for nicotinic receptor systems in the pathophysiology of depression and that nicotinic compounds should be evaluated for treating depression symptoms.

Duke Scholars

Published In

Psychopharmacology (Berl)

DOI

ISSN

0033-3158

Publication Date

November 2006

Volume

189

Issue

1

Start / End Page

125 / 133

Location

Germany

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Severity of Illness Index
  • Saliva
  • Psychiatry
  • Psychiatric Status Rating Scales
  • Nicotinic Agonists
  • Nicotine
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McClernon, F. J., Hiott, F. B., Westman, E. C., Rose, J. E., & Levin, E. D. (2006). Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. Psychopharmacology (Berl), 189(1), 125–133. https://doi.org/10.1007/s00213-006-0516-y
McClernon, F Joseph, F Berry Hiott, Eric C. Westman, Jed E. Rose, and Edward D. Levin. “Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial.Psychopharmacology (Berl) 189, no. 1 (November 2006): 125–33. https://doi.org/10.1007/s00213-006-0516-y.
McClernon FJ, Hiott FB, Westman EC, Rose JE, Levin ED. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2006 Nov;189(1):125–33.
McClernon, F. Joseph, et al. “Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial.Psychopharmacology (Berl), vol. 189, no. 1, Nov. 2006, pp. 125–33. Pubmed, doi:10.1007/s00213-006-0516-y.
McClernon FJ, Hiott FB, Westman EC, Rose JE, Levin ED. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2006 Nov;189(1):125–133.
Journal cover image

Published In

Psychopharmacology (Berl)

DOI

ISSN

0033-3158

Publication Date

November 2006

Volume

189

Issue

1

Start / End Page

125 / 133

Location

Germany

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Severity of Illness Index
  • Saliva
  • Psychiatry
  • Psychiatric Status Rating Scales
  • Nicotinic Agonists
  • Nicotine
  • Male
  • Humans